{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:20:44Z","timestamp":1772050844856,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0243-8","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T11:16:36Z","timestamp":1457608596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial"],"prefix":"10.1186","volume":"9","author":[{"given":"Francine","family":"Foss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubomir","family":"Sokol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Balser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Wolfson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"key":"243_CR1","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011;117:6756\u201367.","journal-title":"Blood"},{"key":"243_CR2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/CCO.0b013e3282ce6f8f","volume":"19","author":"SM Horwitz","year":"2007","unstructured":"Horwitz SM. Management of peripheral T-cell non-Hodgkin\u2019s lymphoma. Curr Opin Oncol. 2007;19:438\u201343.","journal-title":"Curr Opin Oncol"},{"key":"243_CR3","unstructured":"American Cancer Society. Cancer Facts & Figures 2015. 2015; 2015"},{"key":"243_CR4","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"243_CR5","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496\u2013504.","journal-title":"Blood"},{"key":"243_CR6","doi-asserted-by":"crossref","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987\u2013994. doi: 10.1056\/NEJM199309303291402","DOI":"10.1056\/NEJM199309303291402"},{"key":"243_CR7","doi-asserted-by":"crossref","first-page":"Abstract 1614","DOI":"10.1182\/blood.V120.21.1614.1614","volume":"120","author":"FM Foss","year":"2012","unstructured":"Foss FM, Carson KR, Pinter-Brown L, et al. Comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE): first detailed report of primary treatment. Blood. 2012;120:Abstract 1614.","journal-title":"Blood"},{"key":"243_CR8","unstructured":"NCCN clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphomas. V.1.2016"},{"key":"243_CR9","doi-asserted-by":"crossref","first-page":"17-015-0122-8","DOI":"10.1186\/s13045-015-0122-8","volume":"8","author":"C Iragavarapu","year":"2015","unstructured":"Iragavarapu C, Mustafa M, Akinleye A, et al. Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8:17-015-0122-8.","journal-title":"J Hematol Oncol"},{"key":"243_CR10","doi-asserted-by":"crossref","first-page":"abstract 4342","DOI":"10.1182\/blood.V122.21.4342.4342","volume":"122","author":"C Gambacorti-Passerini","year":"2013","unstructured":"Gambacorti-Passerini C, Horibe K, Braiteh F, et al. Safety and clinical activity of crizotinib in patients with ALK-rearranged hematologic malignancies. Blood. 2013;122:abstract 4342.","journal-title":"Blood"},{"key":"243_CR11","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/S2352-3026(15)00023-X","volume":"2","author":"J Dupuis","year":"2015","unstructured":"Dupuis J, Morschhauser F, Ghesquieres H, et al. Combination of romidepsin with cyclosphosphamide, doxorubicin, vinrcristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b\/2 study. Lancet Haematol. 2015;2:e160\u20135.","journal-title":"Lancet Haematol"},{"key":"243_CR12","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","volume":"32","author":"MA Fanale","year":"2014","unstructured":"Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32:3137\u201343.","journal-title":"J Clin Oncol"},{"key":"243_CR13","doi-asserted-by":"crossref","first-page":"abstract 253","DOI":"10.1182\/blood.V126.23.253.253","volume":"126","author":"PB Johnston","year":"2015","unstructured":"Johnston PB, Cashen AF, Nikolinakos PG, et al. Safe and effective treatment of patients with peripheral T-cell lymphoma (PTCL) with the novel HDAC inhibitor, Belinostat, in combination with CHOP: results of the Bel-CHOP phase 1 trial. Blood. 2015;126:abstract 253.","journal-title":"Blood"},{"key":"243_CR14","unstructured":"NCCN clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphoma. V.3.2012"},{"key":"243_CR15","doi-asserted-by":"crossref","first-page":"abstract 8063","DOI":"10.1200\/jco.2012.30.15_suppl.8063","volume":"30","author":"SM Horwitz","year":"2012","unstructured":"Horwitz SM, Delarue R, Lunning MA, et al. Progression-free survival for subsequent relapses in patients with peripheral T-cell lymphoma (PTCL). J Clin Oncol. 2012;30:abstract 8063.","journal-title":"J Clin Oncol"},{"key":"243_CR16","unstructured":"ISTODAX (romidepsin) [package insert]. 2014"},{"key":"243_CR17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"J Clin Oncol"},{"key":"243_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.","journal-title":"J Hematol Oncol"},{"key":"243_CR19","doi-asserted-by":"crossref","first-page":"abstract 8563","DOI":"10.1200\/jco.2014.32.15_suppl.8563","volume":"32","author":"FM Foss","year":"2014","unstructured":"Foss FM, Pro B, Prince HM, et al. Responses to romidepsin by line of therapy in patients with relapsed\/refractory (R\/R) peripheral T-cell lymphoma (PTCL). J Clin Oncol. 2014;32:abstract 8563.","journal-title":"J Clin Oncol"},{"key":"243_CR20","unstructured":"ZOLINZA (vorinostat) [package insert]. 2015."},{"key":"243_CR21","unstructured":"BELEODAQ (belinostat) [package insert]. 2014."},{"key":"243_CR22","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492\u20139.","journal-title":"J Clin Oncol"},{"key":"243_CR23","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1158\/1078-0432.CCR-13-0109","volume":"19","author":"AM Noonan","year":"2013","unstructured":"Noonan AM, Eisch RA, Liewehr DJ, et al. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for KATP channel. Clin Cancer Res. 2013;19:3095\u2013104.","journal-title":"Clin Cancer Res"},{"key":"243_CR24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/cam4.467","volume":"4","author":"PT Sager","year":"2015","unstructured":"Sager PT, Balser B, Wolfson J, et al. Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin. Cancer Med. 2015;4:1178\u201385.","journal-title":"Cancer Med"},{"key":"243_CR25","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2005-03-1306","volume":"107","author":"MA Rizvi","year":"2006","unstructured":"Rizvi MA, Evens AM, Tallman MS, et al. T-cell non-Hodgkin lymphoma. Blood. 2006;107:1255\u201364.","journal-title":"Blood"},{"key":"243_CR26","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"243_CR27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1080\/10428190290026367","volume":"43","author":"M Morgan","year":"2002","unstructured":"Morgan M, Maloney D, Duvic M. Hypomagnesemia and hypocalcemia in mycosis fungoides: a retrospective case series. Leuk Lymphoma. 2002;43:1297\u2013302.","journal-title":"Leuk Lymphoma"},{"key":"243_CR28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2010.06.012","volume":"160","author":"JM Peacock","year":"2010","unstructured":"Peacock JM, Ohira T, Post W, et al. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2010;160:464\u201370.","journal-title":"Am Heart J"},{"key":"243_CR29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3945\/ajcn.112.053132","volume":"98","author":"LC Gobbo Del","year":"2013","unstructured":"Del Gobbo LC, Imamura F, Wu JH, et al. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98:160\u201373.","journal-title":"Am J Clin Nutr"},{"key":"243_CR30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/ndt\/gfm730","volume":"23","author":"A Santoro","year":"2008","unstructured":"Santoro A, Mancini E, London G, et al. Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal. Nephrol Dial Transplant. 2008;23:1415\u201321.","journal-title":"Nephrol Dial Transplant"},{"key":"243_CR31","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1472-8206.2010.00835.x","volume":"24","author":"OE Osadchii","year":"2010","unstructured":"Osadchii OE. Mechanisms of hypokalemia-induced ventricular arrhythmogenicity. Fundam Clin Pharmacol. 2010;24:547\u201359.","journal-title":"Fundam Clin Pharmacol"},{"key":"243_CR32","first-page":"233","volume":"18","author":"N El-Sherif","year":"2011","unstructured":"El-Sherif N, Turitto G. Electrolyte disorders and arrhythmogenesis. Cardiol J. 2011;18:233\u201345.","journal-title":"Cardiol J"},{"key":"243_CR33","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1158\/1078-0432.CCR-05-2095","volume":"12","author":"RL Piekarz","year":"2006","unstructured":"Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res. 2006;12:3762\u201373.","journal-title":"Clin Cancer Res"},{"key":"243_CR34","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1200\/JCO.2005.01.891","volume":"23","author":"ME Juweid","year":"2005","unstructured":"Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin\u2019s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23:4652\u201361.","journal-title":"J Clin Oncol"},{"key":"243_CR35","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/annonc\/mdv010","volume":"26","author":"S Horwitz","year":"2015","unstructured":"Horwitz S, Coiffier B, Foss F, et al. Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:774\u20139.","journal-title":"Ann Oncol"}],"updated-by":[{"DOI":"10.1186\/s13045-017-0518-8","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T00:00:00Z","timestamp":1505692800000}}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0243-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T23:37:57Z","timestamp":1600299477000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jhoonline.org\/content\/9\/1\/22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["243"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0243-8","relation":{"erratum":[{"id-type":"doi","id":"10.1186\/s13045-017-0518-8","asserted-by":"object"}]},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]},"article-number":"22"}}